A real-world study of camrelizumab in the treatment of hepatocellular carcinoma.

e16121Background: Programmed cell death protein‐1(PD-1) targeted immunotherapy is a promising treatment strategy for advanced hepatocellular carcinoma. Anti-PD-1 inhibitor camrelizumab showed antit...